Cargando…

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

BACKGROUND: Immunotherapy using high dose interleukin-2 (HD IL2) in patients with renal cell carcinoma (RCC) and melanoma is associated with severe toxicities. The association between annual hospital volume of HD IL2 and inpatient mortality is not well studied. In this study we aim to quantify the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, Kathan, Appleman, Leonard, Wang, Hong, Tarhini, Ahmad A., Parikh, Rahul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723120/ https://www.ncbi.nlm.nih.gov/pubmed/26799322 http://dx.doi.org/10.1371/journal.pone.0147153

Ejemplares similares

Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
por: Mehta, Kathan, et al.
Publicado: (2015)

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
por: Achkar, Tala, et al.
Publicado: (2017)

Overall survival based on oncologist density in the United States: A retrospective cohort study
por: Siddappa Malleshappa, Sudeep K., et al.
Publicado: (2021)

Immunotherapy in genitourinary malignancies
por: Mehta, Kathan, et al.
Publicado: (2017)

Renal Medullary Carcinoma: Case Report of an Aggressive Malignancy with Near-Complete Response to Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy
por: Amjad, Ali Imran, et al.
Publicado: (2014)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
por: Parikh, Rahul A, et al.
Publicado: (2014)

The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma
por: Pachella, Laura A., et al.
Publicado: (2015)

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
por: Nguyen, Nghi C., et al.
Publicado: (2016)

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
por: Ahmed, F. Y., et al.
Publicado: (1996)

Annual relative increased in inpatient mortality from antimicrobial resistant nosocomial infections in Thailand
por: Phodha, T., et al.
Publicado: (2019)

The use of immunotherapy in the treatment of melanoma
por: Achkar, Tala, et al.
Publicado: (2017)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
por: Dutcher, Janice P, et al.
Publicado: (2014)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

Update on vaccine development for renal cell cancer
por: Chi, Nina, et al.
Publicado: (2010)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

Thirty-day readmissions due to Venous thromboembolism in patients discharged with syncope
por: Siddappa Malleshappa, Sudeep K., et al.
Publicado: (2020)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Association of annual hospital septic shock case volume and hospital mortality
por: Chen, Yan, et al.
Publicado: (2022)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Variation in Annual Volume at a University Hospital Does Not Predict Mortality for Pancreatic Resections
por: Mukhtar, Rita A., et al.
Publicado: (2008)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Inpatient Management of Pulmonary Embolism: Clinical Characteristics and Mortality in a High-Volume Tertiary Care Center
por: Mudrakola, Harsha V., et al.
Publicado: (2022)

Determinants of renal recovery and mortality inpatients undergoing continuous renal replacement therapy in the ICU
por: Gleeson, PJ, et al.
Publicado: (2015)

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
por: Eljilany, Islam, et al.
Publicado: (2023)

Interleukins in the treatment of melanoma
por: Xu, Xinyuan, et al.
Publicado: (2022)

Integers: annual volume 2013
por: Landman, Bruce
Publicado: (2014)

Our Annual Volume of Transactions
Publicado: (1883)

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
por: Lissoni, P., et al.
Publicado: (1994)

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
por: Payne, Roxanne, et al.
Publicado: (2014)

Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
por: Bulgarelli, Jenny, et al.
Publicado: (2021)

Robust tumor immunity to melanoma mediated by interleukin 9
por: Purwar, Rahul, et al.
Publicado: (2012)

Unplanned 30-Day Hospital Readmissions of Symptomatic Carotid and Vertebral Artery Dissection
por: Mehta, Tapan, et al.
Publicado: (2018)

Improving pneumococcal vaccination rates of medical inpatients in urban Nepal using quality improvement measures
por: Bock, Allison, et al.
Publicado: (2016)

Annual Case Volume and One-Year Mortality for Endovascular Treatment in Acute Ischemic Stroke
por: Kim, Jun Yup, et al.
Publicado: (2022)

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
por: Vlasveld, L. T., et al.
Publicado: (1992)

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
por: Vlasveld, L. T., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_v94t6lvrd73hr49gl6of3qd10b